SCHEMBL24012702

SCHEMBL24012702

O=C(NCCCOc1ccc2c(c1)c(-c1ccc(F)c(CO)c1)nn2C1CCCCO1)OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.39
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTR3A P46098 1/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
FLT1 P17948 3/20 0.34
KDR P35968 3/20 0.34
FLT3 P36888 3/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
DNMT3A Q9Y6K1 1/20 0.34
PLA2G4A P47712 1/20 0.34
AURKA O14965 1/20 0.34
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28989809 0.96 BRD4 (0.41) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL30242656 0.93 BRD4 (0.41) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL30242724 0.93 BRD4 (0.39) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL24013067 0.93 BRD4 (0.41) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL24012476 0.93 BRD4 (0.39) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL24012478 0.92 BRD4 (0.39) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL30242692 0.92 BRD4 (0.39) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL24013151 0.90 BRD4 (0.41) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL28989548 0.88 BRD4 (0.40) BRD4MAPTL3MBTL1HTR3APPARG
SCHEMBL24012643 0.86 BRD4 (0.38) BRD4MAPTL3MBTL1HTR3APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors ONCODESIGN PRECISION MEDICINE (FR) 2026-02-10 US disclosed
EP-4146658-B1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PREC MEDICINE OPM (FR) 2025-10-29 EP disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US disclosed
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS ONCODESIGN PRECISION MEDICINE (FR) 2023-11-09 US disclosed
EP-4146658-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2023-03-15 EP disclosed
WO-2021224320-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2021-11-11 WO disclosed
WO-2021224320-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LES LABORATOIRES SERVIER (FR) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545689-B2 Macrocyclic LRRK2 kinase inhibitors LRRK2, SNCA, ROS1 BRD4 1490/4885MAPT 717/4885L3MBTL1 198/4885
US-20230357269-A1 NEW MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, RIN1, GRK3 BRD4 803/4885MAPT 645/4885L3MBTL1 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.